Physician profile
Bailey Croyle
NPI 1578169215
$3,000.09
in general payments reported to CMS, 2019-2025
22 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $315 · 2023: $872 · 2024: $985 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,157.39 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $471.82 | 2021-2025 | Relistor |
| Pfizer INC. | $388.06 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $208.54 | 2024-2025 | Belbuca, Xtampza |
| Medtronic, INC. | $120.40 | 2022 | |
| Amgen INC. | $101.14 | 2021 | |
| Redhill Biopharma INC. | $96.41 | 2021 | |
| Averitas Pharma INC. | $67.29 | 2024 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $58.13 | 2022 | |
| Ferring Pharmaceuticals INC. | $40.80 | 2024-2025 | Euflexxa |
| Vertex Pharmaceuticals Incorporated | $37.40 | 2025 | |
| Fidia Pharma USA INC. | $32.12 | 2022 | |
| Depuy Synthes Sales INC. | $32.00 | 2023-2024 | Monovisc, Orthovisc |
| Teva Pharmaceuticals USA, INC. | $31.82 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $29.41 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $25.00 | 2024 | |
| Biotronik Nro, INC. | $23.81 | 2025 | Prospera |
| Ibsa Pharma INC. | $20.44 | 2024 | Licart, Tirosint |
| Electronic Waveform Lab, INC. | $15.51 | 2021-2024 | |
| Virtus Pharmaceuticals LLC | $15.40 | 2021 | |
| Bioventus LLC | $14.67 | 2021 | |
| Uswm, LLC | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Croyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.